Home LiteratureArticle Details
PMID: 15389787 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.

The Prostate ·Vol. 62 ·No. 3 ·2005-02-15 ·Pages 299-306

Frønsdal K, Saatcioglu F

Abstract

Histone deacetylase (HDAC) inhibitors have shown significant anti-proliferative and apoptotic properties on various cancer cells, including prostate cancer, and are therefore being evaluated as treatment modalities. However, the specific effect of HDAC inhibitors on androgen-sensitive and androgen-independent cell lines have not been thoroughly studied which we hypothesized could be different. We therefore assessed whether three structurally unrelated HDAC inhibitors, trichostatin A (TSA), depsipeptide (FR901228), and sodium butyrate, affect cell death in the prostate cancer cell lines LNCaP, DU-145, and PC-3. To investigate the extent and the nature of cell death, we used Trypan blue exclusion assay, phase-contrast light microscopy, fluorescence microscopy, and Western blot analyses. At concentrations where they potentiate transcriptional activation, all three HDAC inhibitors induced cell death in LNCaP and DU-145 cells, but not in PC-3 cells, within the timeline of the experiments. HDAC inhibitor-induced cell death in LNCaP and DU-145 cells showed several characteristic apoptotic features, such as cell shrinkage, nuclear condensation, and poly(ADP) ribose polymerase cleavage. However, there were differences in the way LNCaP and DU-145 cells responded to treatment with various HDAC inhibitors. For example, whereas TSA and FR901228 were more effective in inducing apoptosis in LNCaP cells compared with DU-145 cells, the reverse was true for sodium butyrate. Moreover, within the same cell line, TSA, FR901228, and sodium butyrate exhibited different potencies for induction of apoptosis. Collectively, these results suggest that the response of prostate cancer cells to HDAC inhibitors is not uniform, but cell line and inhibitor specific. Given that prostate cancer is generally a multiclonal disease representing different cell lineages, it is important to develop HDAC inhibitors that will be effective against all of these cell types.

MeSH Terms
Apoptosis/drug effects Blotting, Western Butyrates/pharmacology Cell Line, Tumor Depsipeptides/pharmacology Enzyme Inhibitors/pharmacology Histone Deacetylase Inhibitors Histone Deacetylases/metabolism Humans Hydroxamic Acids/pharmacology Indoles/chemistry Male Microscopy, Fluorescence Microscopy, Phase-Contrast Poly Adenosine Diphosphate Ribose/metabolism Prostatic Neoplasms/drug therapy,enzymology,pathology Trypan Blue/chemistry
Chemicals
Butyrates Depsipeptides Enzyme Inhibitors Histone Deacetylase Inhibitors Hydroxamic Acids Indoles Poly Adenosine Diphosphate Ribose trichostatin A DAPI Histone Deacetylases Trypan Blue
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Frønsdal Katrine
Department of Molecular Biosciences, University of Oslo, Oslo, Norway.
Saatcioglu Fahri
Article Info
Journal
The Prostate
Abbr.
Prostate
ISSN
0270-4137
Published
2005-02-15
Pages
299-306
Language
English
Region
United States
NLM ID
8101368
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com